Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation
| Autor: | N. Puig, Juan Montoro, Inés Gómez, Pilar Solves, Pau Montesinos, Miguel A. Sanz, Carmen Freiria, Marta Santiago, Ana Villalba, Nelly Carpio, José Luis Piñana, Guillermo Sanz, Lorenzo Ji, Jaime Sanz |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Graft Rejection Male medicine.medical_specialty Adolescent medicine.medical_treatment CD34 Platelet Transfusion Hematopoietic stem cell transplantation Young Adult 03 medical and health sciences 0302 clinical medicine Risk Factors medicine Humans Transplantation Homologous Platelet Treatment Failure Aged Retrospective Studies Umbilical Cord Blood Transplantation business.industry Hematopoietic Stem Cell Transplantation Hematology General Medicine Middle Aged Survival Analysis Surgery Platelet transfusion refractoriness Transplantation Platelet transfusion Hematologic Neoplasms 030220 oncology & carcinogenesis Female Stem cell business 030215 immunology |
| Zdroj: | Annals of Hematology. 97:161-167 |
| ISSN: | 1432-0584 0939-5555 |
| DOI: | 10.1007/s00277-017-3168-6 |
| Popis: | Hematopoietic stem cell transplantation has been considered a risk factor for development of platelet transfusion refractoriness. The objective of this study was to assess the platelet transfusion refractoriness rate in patients undergoing allogeneic hematopoietic stem cell transplantation from different sources. We retrospectively reviewed the charts and transfusion records of patients who underwent allogeneic stem cell transplantation at our institution between 2013 and 2015. The evaluation of post-transfusion platelet count was assessed for each transfusion given, from day of progenitor infusion to day 30 after transplantation. Of 167 patients included in this study, 101 received peripheral blood stem cell transplantation (PBSCT) and 66 received umbilical cord blood transplantation (UCBT). Overall, the percentage of platelet transfusions with a 14-h CCI lower than 5000 was 59.3%, being these data significantly higher for UCBT (67.6%) than for PBSCT (31.0%). Seventy-eight percent of patients underwent UCBT become refractory, while 38.6% of patients who received PBSCT were refractory. Factors associated to platelet refractoriness were lower CD34+ cell dose infused, higher number of antibiotics used, presence of anti-HLA I antibodies, and reduced-intensity conditioning regimen. Platelet refractoriness is a frequent and complex adverse event and remains a therapeutic challenge in the management of patients undergoing HSCT. There is a higher rate of platelet refractoriness in patients who received UCBT as compared to patients who received PBSCT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink